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Abstract   
Folate is essential for normal cell division and 
as intrauterine fetal growth involves a process of 
rapidly dividing cells, there is a consequent 
increased requirement for folate at this time. Folate, 
and the synthetic form folic acid, is thus vital for 
the early development process of a healthy fetus 
and there is indisputable evidence that it can 
significantly reduce the risk of neural tube defects 
(NTDs).  Further ongoing research suggests that 
folic acid supplementation in pregnancy is also 
associated with a decreased risk of other birth 
defects. This review gives an overview of the 
current literature related to the use of folic acid in 
the peri-conceptional period and prevention of birth 
defects, in particular NTDs. 
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Introduction 
It has long been acknowledged that “a healthy 
start in life must be a top priority for any 
society”(WHO, 1998 p.21).1 Achieving optimal 
maternal and infant health is an important goal for 
all health care systems and is emphasized in the 
WHO Millennium Development Goals.2  Today, 
congenital anomalies are among the major causes of 
perinatal and infant mortality and morbidity in 
developed countries.3 It is known that avoidance of 
certain environmental exposures, adequate 
nutrition, folate and other vitamin intake, cessation 
of smoking and alcohol consumption, prevention 
and control of maternal infection and disease are 
among the interventions that may avoid congenital 
anomalies.4 Nevertheless, many fetuses still suffer 
from potentially avoidable birth defects and this is 
an important area where public health initiatives 
and interventions can be effective in the primary 
prevention of congenital anomalies. 
This review outlines the current knowledge 
related to the use of folic acid in the prevention of 
severe birth defects.  
 
Folate and folic acid 
Folate is one of the water-soluble B vitamins; 
Folic Acid (FA) is the synthetic form of this 
vitamin and is only minimally different from folate. 
FA has the advantage of being better absorbed by 
the body and having a much higher bioavailability 
than naturally occurring folate.5 
Being water soluble, folate is easily excreted 
by the body and is not stored, such that an adequate 
daily intake is necessary to maintain the required 
blood levels of this vitamin. The National Institute 
of Health – Office of Dietary Supplements in the 
UK6 gives the daily recommended dietary 
allowance (RDA) of folate for an adult male or 
female as 400 micrograms, this requirement 
increases to 600 micrograms of dietary folate in 
pregnancy. Folate is found naturally in several 
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foods including liver, yeast, leafy green vegetables, 
such as spinach, various fruits including oranges, 
eggs and beans.6 
Folate is known to be important for the 
formation of red and white blood cells, proper 
development of the fetus and the formation of 
nucleic acids in DNA (deoxyribonucleic acid) and 
RNA (ribonucleic acid)6. Folates also play an 
important role in homocysteine metabolism, with 
folate having a homocysteine lowering effect.7 
Adequate blood folate levels have been 
documented to be associated with several beneficial 
health effects; however, the most notable are the 
health benefits associated with maternal and fetal 
health.8  
 
Folate and maternal, fetal and perinatal health 
Low maternal blood folate levels have long 
been implicated in increased risk of megaloblastic 
anaemia necessitating treatment with FA.9 More 
recently, low folate levels have been associated 
with low birth weight;10 the affect believed to be 
mediated through plasma homocysteine 
metabolism, with folate acting to decrease 
harmfully high homocysteine levels.11 Low birth 
weight is associated with poor perinatal outcomes 
including higher mortality and morbidity as well as 
long term motor and cognitive disorders12 and 
increased risks of cardiovascular and metabolic 
disease later on in the infant’s life.13  
Bergen et al. (2012)11 showed that “women 
with high homocysteine and low folate 
concentrations have lighter placentas and lower 
birth weight by 110 and 124g, respectively” 
(p.748). These are significant findings as “these 
estimates are of similar magnitude to, for example, 
smoking, which is a well-established risk factor for 
impaired fetal growth” (p.748). 
Other adverse pregnancy outcomes that have 
been associated with low maternal folate include 
prematurity, pre-eclampsia and spontaneous 
pregnancy loss,14 however these associations have 
not been confirmed.15 
Inadequate maternal blood folate levels have 
also recently been associated with poorer infant 
neurodevelopment including language delay,16 
impaired attention function and autism17. The 
results of these studies are, however, conflicting and 
inconclusive and further research to determine the 
exact association, if any, is required. 
The most significant and widely researched 
associations of low maternal folate levels have been 
with the occurrence of certain birth defects namely 
neural tube defects (NTDs). 
 
Folic acid and neural tube defects 
NTDs are major birth defects resulting from 
inappropriate development of the neurological 
system in early embryonic growth (Fig. 1) and 
occur with a prevalence of around 1 in 1,000 births 
in Europe.18 The major NTDs encountered are 
anencephaly and spina bifida, which occur when the 
neural tube fails to close. These defects are 
associated with severe morbidity and mortality, 
causing distress to both the individual and his 
family and presenting a significant burden to public 
health.19  
Figure 1: Embryonic development and spina 
bifida (By permission of Mayo Foundation for 
Medical Education and Research. All rights 
reserved, http://www.mayoclinic.org/diseases-
conditions/spina-bifida/multimedia/spina-
bifida/img-20006705) 
 
 
 
 
 
 
 
 
 
 
 
 
Obladen (2011),20 in his paper titled ‘Cats, 
Frogs and Snakes: Early Concepts of Neural Tube 
Defects’, describes the colourful history of the 
various beliefs regarding the causation of these 
defects. He describes how in the past these infants 
were considered as ‘human monsters’. In the 16th 
century such defects were attributed to 
“imagination, God’s glory, God’s wrath and 
demons and devils” (p.1454); in the 18th and 19th 
centuries the predominant belief was that these 
defects resulted primarily from the mother’s 
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imagination and experiences during pregnancy. 
However, in spite of this generally held idea, some 
eminent scientists of the time did doubt that 
imagination would impinge so significantly on the 
formation of the infant.20 It was only in the late 18th 
and early 19th century that the embryogenic 
formation and closure of the neural tube was 
described.21 In the 20th century, several 
epidemiological studies observed regional and 
socioeconomic differences in the prevalence of 
NTDs, implicating the role of environmental factors 
in the causation of NTDs.22 It was not until 1965 
that folate deficiency was associated with the 
occurrence of NTDs.23 Current understanding is that 
NTDs are associated with folate deficiency and 
disturbed methylenetetrahydrofolate reductase 
(MTHFR) metabolism,24 however, as Blom et al. 
(2006)25 describe, “the case is far from closed” 
(p.724) and further research into the causation of 
NTDs is ongoing.  
Evidence of a possible relationship between 
defective folate metabolism in the mother and 
embryopathy was first raised in the mid-1960s23 
and the possible role of blood folate deficiency in 
the occurrence of NTDs was described by Smithells 
et al. in 1976.26 In 1981, Smithells et al. 27 
published the results of a multicentre, case-control 
study in which women who had previously given 
birth to an infant with NTD and were planning to 
become pregnant again were offered a multivitamin 
containing, amongst others, 360ug of FA. These 
women were advised to take the multivitamin at 
least 28 days prior to conception. Results of this 
study showed a 4% recurrence rate of infants with 
NTDs in those women who had no vitamin 
supplementation as opposed to a 0.4% recurrence in 
those women who had vitamin supplementation. 
The authors concluded that “the most likely 
explanation is that supplementation has prevented 
some neural tube defects” (p.911).  
Further corroborating these findings, Laurence 
et al. (1981)28 report on a double-blind randomised 
controlled trial conducted in Wales, which engaged 
111 women who had had a previous child with 
NTD. In this study, it was not a multi-vitamin, but 
specifically FA that was given to these women. 
Sixty women were advised to take 4mg of folic acid 
daily before and during early pregnancy (of these 
44 complied while 16 defaulted) and 51 women 
were given a placebo. The researchers reported that 
there were no recurrences in those mothers who had 
complied with treatment (n=44), 2 recurrences in 
mothers who had not complied (12.5%, n=16) and 4 
recurrences in those women taking a placebo (7.8%, 
n=51); these findings were significant, p=0.04.28 
These studies were followed by a number of others 
demonstrating the prevention of recurrence of 
NTDs using FA supplementation.29-30  
In July 1983, the Medical Research Council 
Vitamin Study Research Group31 launched a large 
randomised double-blind prevention trial involving 
33 centres from 7 different countries to determine 
whether peri-conceptional supplementation (before 
and until 12 weeks of pregnancy)  with FA and/or 
other vitamins could prevent recurrence of NTDs in 
women with a history of NTD infants. Results of 
this landmark trial were published in The Lancet in 
July 1991. This trial clearly showed that FA had “a 
72% protective effect” (p.131) for recurrence in 
those women who had had a previous infant with 
NTD.31 
In 1992, Czeizel and Dudas32 carried out a 
double blind randomised controlled trial in women 
planning a pregnancy and not having a history of an 
infant with NTD. The women were randomised to 
either having a multivitamin supplement 
(containing, amongst others, 800ug of FA) or a 
mineral-only supplement starting at least one month 
before the intended conception. Pregnancy 
outcomes of the two study groups were evaluated 
and a significantly lower rate of NTDs was 
encountered in the group taking multivitamins. 
None of the 2,394 mothers taking multivitamins 
including FA had a baby with NTD whereas 6 of 
the 2,310 mothers taking minerals without 
multivitamins had a baby with NTD, with 
p=0.029.32 In this milestone study, the authors 
concluded that “peri-conceptional vitamin 
supplementation reduced the incidence of a first 
occurrence of neural tube defects” (p.1834).  
Following these breakthrough findings in the 1980s 
and early 1990s, a large number of studies further 
establishing the protective role of FA in preventing 
NTDs, have been published.33–35  
Berry et al. (1999),36 carrying out community-
based intervention studies in two regions of China, 
demonstrated that daily supplementation with 
400ug of FA alone could prevent these defects both 
in areas of high incidence as well as in areas with 
low incidence of NTDs. The reduction being more 
marked in the areas of high incidence.  
Three Cochrane Systematic Reviews with 
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meta-analyses examining the relationship between 
FA and NTDs have been carried out by De-Regil et 
al. in 2010,37 Lumley et al. in 201138, and De-Regil 
et al. in 2015,39 all concluding that peri-
conceptional FA has a protective effect against 
NTDs.  
In summary, research has convincingly shown 
that peri-conceptional FA intake (from at least one 
month before conception to 12 weeks of pregnancy) 
can decrease the rate of NTDs by 50% for the first 
occurrence and up to 70% for recurrence if taken at 
the correct time,31,40 giving good scope for action to 
actively prevent these defects.  
To obtain maximum benefits the optimal time 
of taking FA to avoid preventable NTDs is to start 
supplementation at least one month before 
conception until at least one month after as the 
development of the neural tube occurs early in 
embryological development.38 The dose of peri-
conceptional FA advised for women to reach the 
required blood folate status is 400ug daily in 
women with the lowest risk of NTDs and 4mg daily 
in high-risk women with a history of NTDs or 
women with certain chronic disease, including 
epilepsy treated with anti-epileptic drugs.41 Recent 
research also shows benefits of folic acid 
supplementation for the male partner with a 
personal history of NTDs.42 
 
Folic acid and other birth defects 
Ever since the protective influence of peri-
conceptional FA supplementation on the occurrence 
of NTDs was described, interest in possible 
associations between maternal FA supplementation 
and the occurrence of other birth defects has 
grown.43-44 In an extensive systematic review of 
studies investigating associations between 
multivitamins containing FA and various birth 
defects, Botto et al. (2004) found that peri-
conceptional multivitamin use was associated with 
an overall decreased risk of congenital anomalies 
which was not due solely to the decrease in NTDs.44 
There is evidence that FA may decrease the 
occurrence of congenital heart defects.43,45 A 
European registry-based case-control study by Van 
Beynum et al.46 in 2010 analysing birth defects in 
the Northern Netherlands over a 10-year period 
(1996 to 2005) showed a decreased risk of all types 
of congenital heart disease with peri-conceptual FA 
use. The authors conclude that FA may decrease the 
prevalence of congenital heart disease by 
approximately 20%.46 
There is emerging evidence of a protective 
role of FA in the prevention of orofacial clefts47 and 
abdominal wall defects namely gastroschisis and 
omphalocele.48-49 However, these claims have not 
been conclusively confirmed and remain 
debatable.37,39 
 
Conclusion 
Evidence for the protective function of FA in 
prevention of NTDs, when taken prior to 
conception and throughout the first trimester of 
pregnancy, is indisputable. Research showing 
protection against other birth defects including 
congenital heart, orofacial clefts and abdominal 
wall defects is less so, rendering definitive 
conclusions at this time premature. 
Maximising the intake of folic acid in the 
peri-conceptional period is truly an area where 
public health action can concretely contribute to the 
decrease of severe, disabling and potentially lethal 
NTDs. 
 
References  
1.  World Health Organisation. Health 21 Targets.; 1998. 
http://www.euro.who.int/_data/assets/pdf_file/0004/109
759/EHFA5-E.pdf. 
2.  World Health Organisation. Millenium Development 
Goals. 2015. 
http://www.who.int/mediacentre/factsheets/fs290/en/. 
3.  Rosano A, Botto LD, Botting B, Mastroiacovo P, 
Germany W. Infant mortality and congenital anomalies 
from 1950 to 1994 : an international perspective. J 
Epidemiol Community Health. 2000;54(9):660-666. 
4.  Dolk H. What is the “primary” prevention of congenital 
anomalies? Lancet. 2009;374(9687):378. 
5.  Winkels R., Brouwer IA, Siebelink E, Katan MB, 
Verhoef P. Bioavailability of food folates is 80% of that 
of folic acid. Am J Clin Nutr. 2007;85:465-473. 
6.  National Institutes of Health. Dietary Supplement Fact 
Sheet - Folate.; 2012. 
http://ods.od.nih.gov/pdf/factsheets/Folate-
HealthProfessional.pdf. 
7.  Clarke R, Homocysteine Lowering trialists 
Collaboration. Dose-dependent effects of folic acid on 
blood concentrations of homocysteine : a meta-analysis 
of the randomized trials. Am J Clin Nutr. 2005;82:806-
812. 
8.  Tamura T, Picciano M. Folate and human reproduction. 
Am J Clin Nutr. 2006;83:993-1016. 
9.  Chanarin I, MacGibbon B, O’Sullivan W, Mollin D. 
Folic-acid deficiency in pregnancy - The pathogenesis 
of megaloblastic anaemia of pregnancy. Lancet. 
1959;2(7104):634-639. 
 
 
 
52
gOdRe 
 
 
 
Review Article 
 
 
 
Malta Medical Journal    Volume 28 Issue 04 2016                                                                                                                
 
 
10.  Timmermans S, Jaddoe V, Hofman A, Steegers-
Theunissen R, Steegers E. Periconception folic acid 
supplementation, fetal growth and the risks of low birth 
weight and preterm birth: the Generation R Study. Br J 
Nutr. 2009;102(5):777-785. 
11.  Bergen NE, Jaddoe VW, Timmermans S, Hofman A, 
Lindemans J, Russcher H, et al. Homocysteine and 
folate concentrations in early pregnancy and the risk of 
adverse pregnancy outcomes: The generation R study. 
BJOG An Int J Obstet Gynaecol. 2012;119(6):739-751. 
12.  Wilcox AJ. On the importance--and the unimportance--
of birthweight. Int J Epidemiol. 2001;30(6):1233-1241. 
13.  Barker DJ, Gluckman PD, Godfrey KM, Harding JE, 
Owens JA, Robinson JS. Fetal nutrition and 
cardiovascular disease in adult life. Lancet. 
1993;341(8850):938-941. 
http://www.ncbi.nlm.nih.gov/pubmed/8096277. 
14.  Dodds L, Fell DB, Dooley KC, Armson BA, Allen AC, 
Nassar BM, et al. Effect of homocysteine concentration 
in early pregnancy on gestational hypertensive 
disorders and other pregnancy outcomes. Clin Chem. 
2008;54(2):326-334. 
15.  Lassi Z, Salam R, Haider B, Bhutta Z. Folic acid 
supplementation during pregnancy for maternal health 
and pregnancy outcomes ( Review ). Cochrane database 
Syst Rev. 2013;(3):CD006896. 
16.  Roth C, Magnus P, Schjølberg S, Stoltenberg C, Suren 
P, McKeague IW, et al. Folic acid supplements in 
pregnancy and severe language delay in children. 
JAMA. 2011;306(14):1566-1573. 
17.  Schmidt RJ, Tancredi DJ, Ozonoff S, Hansen RL, 
Hartiala J, Allayee H, et al. Maternal periconceptional 
folie acid intake and risk of autism spectrum disorders 
and developmental delay in the CHARGE (CHildhood 
Autism Risks from Genetics and Environment) case-
control study. Am J Clin Nutr. 2012;96(1):80-89. 
18.  Eurocat Folic Acid Working Group. Special Report: 
Prevention of Neural Tube Defects by Periconceptional 
Folic Acid Supplementation in Europe. 
2009;44(December). http://www.eurocat-
network.eu/content/Special-Report-NTD-3rdEd-Part-
I.pdf. 
19.  Sawin KJ, Thompson NM. The Experience of Finding 
an Effective Bowel Management Program for Children 
With Spina Bifida: The Parent’s Perspective. J Pediatr 
Nurs. 2009;24(4):280-291. 
20.  Obladen M. Cats, Frogs, and Snakes: Early Concepts of 
Neural Tube Defects. J Child Neurol. 
2011;26(11):1452-1461. 
21.  Glaser O. The thoery of autonomous folding in 
embryogenesis. Science (80- ). 1916;44(1136):505-509. 
22.  Hewitt D. Geographical variations in the mortality 
attributed to spina bifida and other congenital 
anomalies. Brit J Prev Soc Med. 1963;17(13):13-22. 
23.  Hibbard ED, Smithells R. Folic Acid Metabolism and 
Human Emryopathy. Lancet. 1965;1(7398):1254. 
24.  Blom HJ. Folic acid, methylation and neural tube 
closure in humans. Birth Defects Res Part A - Clin Mol 
Teratol. 2009;85(4):295-302. 
 
 
25.  Blom HJ, Shaw GM, den Heijer M, Finnell RH. Neural 
tube defects and folate: case far from closed. Nat Rev 
Neurosci. 2006;7(9):724-731. 
26.  Smithells RW, Sheppard S, Schorah CJ. Vitamin 
deficiencies and neural tube defects. Arch Dis Child. 
1976;51(12):944-950. 
27.  Smithells R, Sheppard S, Schorah CJ, Seller MJ, Nevin 
NC, Harris R, et al. Apparent prevention of neural tube 
defects by periconceptional vitamin supplementation. 
Arch Dis Child. 1981;56:911-918. 
28.  Laurence KM, James N, Miller MH, Tennant GB, 
Campbell H. Double-blind randomised controlled trial 
of folate treatment before conception to prevent 
recurrence of neural-tube defects. BMJ. 
1981;282(6275):1509-1511. 
29.  Kirke PN, Daly LE, Elwood JH. A randomised trial of 
low dose folic acid to prevent neural tube defects. The 
Irish Vitamin Study Group. Arch Dis Child. 
1992;67:1442-1446. 
30.  Mulinare J, Cordero J, Erickson JD, Berry R. 
Periconceptional Use of Multivitamins and the 
Occurrence of Neural Tube Defects. JAMA. 
1988;260(21):3141-3145. 
31.  MRC Vitamin Study Research Group. Prevention of 
neural tube defects : Results of the Medical Research 
Council Vitamin Study. Lancet. 1991;338(8760):131-
137. 
32.  Czeizel AE, Dudás I. Prevention of the first occurrence 
of neural-tube defects by periconceptional vitamin 
supplementation. N Engl J Med. 1992;327(26):1832-
1835. 
33.  Werler MM, Shapiro S, Mitchell AA. Periconceptional 
folic acid exposure and risk of occurrent neural tube 
defects. JAMA. 1993;269(10):1257-1261. 
34.  Agarwal SS. Multicentric study of efficacy of 
periconceptional folic acid containing vitamin 
supplementation in prevention of open neural tube 
defects from India. Indian J Med Res. 2000;122:206-
211. 
http://onlinelibrary.wiley.com/o/cochrane/clcentral/artic
les/155/CN-00328155/frame.html. 
35.  Chen G, Song X, Ji Y, Zhang L, Pei L, Chen J, et al. 
Prevention of NTDs with periconceptional 
multivitamin supplementation containing folic acid in 
China. Birth Defects Res Part A - Clin Mol Teratol. 
2008;82(8):592-596. 
36.  Berry RJ, Zhu L, Erickson JD, Li S, Moore CA, Wang 
H, et al. Prevention of neural tube defects with folic 
acid in China. N Engl J Med. 1999;341(20):1485-1490. 
37.  De-Regil LM, Fernández-Gaxiola AC, Dowswell T, 
Peña JP. Effects and safety of periconceptional folate 
supplementation for preventing birth defects. Cochrane 
Database Syst Rev. 2010;2(10):1-135. 
38.  Lumley J, Watson L, Watson M, Bower C. 
Periconceptional supplementation with folate and/or 
multivitamins for preventing neural tube defects. 
Cochrane Database Syst Rev. 
2001;(3):Art.No.CD001056. 
 
 
 
53
gOdRe 
 
 
 
Review Article 
 
 
 
Malta Medical Journal    Volume 28 Issue 04 2016                                                                                                                
 
 
39.  De-Regil LM, Peña-Rosas JP, Fernández-Gaxiola AC, 
Rayco-Solon P. Effects and safety of periconceptional 
oral folate supplementation for preventing birth defects. 
Cochrane database Syst Rev. 2015;12(12):CD007950. 
40.  Daly S, Mills JL, Molloy A, Conley M, Lee YJ, Kirke 
PN, et al. Minimum effective dose of folic acid for food 
fortification to prevent neural tube defects. Lancet. 
1997;350:1666-1669. 
41.  CDC (Center for Disease Control). Recommendations 
for the use of folic acid to reduce the number of cases 
of spina bifida and other neural tube defects. MMWR. 
1992;41(RR-14):1-7. 
42.  Douglas Wilson R, Audibert F, Brock JA, Carroll J, 
Cartier L, Gagnon A, et al. Pre-conception Folic Acid 
and Multivitamin Supplementation for the Primary and 
Secondary Prevention of Neural Tube Defects and 
Other Folic Acid-Sensitive Congenital Anomalies. J 
Obstet Gynaecol Canada. 2015;37(6):534-549. 
43.  Czeizel AE. Periconceptional folic acid and 
multivitamin supplementation for the prevention of 
neural tube defects and other congenital abnormalities. 
Birth Defects Res Part A - Clin Mol Teratol. 
2009;85(4):260-268. 
44.  Botto LD, Olney RS, Erickson JD. Vitamin 
supplements and the risk for congenital anomalies other 
than neural tube defects. Am J Med Genet C Semin 
Med Genet. 2004;125C(1):12-21. 
45.  Bailey LB, Berry RJ. Folic acid supplementation and 
the occurrence of congenital heart defects, orofacial 
clefts, multiple births, and miscarriage. Am J Clin Nutr. 
2005;81(5):1213S-1217S. 
46.  Van Beynum IM, Kapusta L, Bakker MK, Den Heijer 
M, Blom HJ, De Walle HEK. Protective effect of 
periconceptional folic acid supplements on the risk of 
congenital heart defects: A registry-based case-control 
study in the northern Netherlands. Eur Heart J. 
2010;31(4):464-471. 
47.  Kelly D, O’Dowd T, Reulbach U. Use of folic acid 
supplements and risk of cleft lip and palate in infants: a 
population-based cohort study. Br J Gen Pract. 
2012;62(600):e466-72. 
48.  Paranjothy S, Broughton H, Evans A, Huddart S, 
Drayton, M, Jefferson R, et al. The role of maternal 
nutrition in the aetiology of gastroschisis: An incident 
case-control study. Int J Epidemiol. 2012;41(4):1141-
1152. 
49.  Mills JL, Carter TC, Kay DM, Browne m, Brody LC, 
Liu A, et al. Folate and Vitamin B12 Related Genes and 
Risk for Omphalocele. Hum Genet. 2012;131(5):739-
746.  
 
54
